Home > Focus Areas > DLBCL Connect > Post
4yr
L-MIND Trial Results Show CD19 Antibody Is Reasonable in R/R DLBCL
Source : https://www.targetedonc.com/view/l-mind-trial-results-show-cd19-antibody-is-reasonable-in-r-r-dlbcl
During a Targeted Oncology Case Based Peer Perspectives Roundtable event, Loretta J. Nastoupil, MD, associate professor, director, Lymphoma Outcomes Database, section chief, New Drug Development, in the Department of Lymphoma/Myeloma, Division Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discussed the case of a 74-year-old patients with diffuse large B-cell lymphoma.
-
Mark Fesler4yrWe know from prior studies that lenalidomide carries a reasonable signal of efficacy, both in terms of response rate and prolonged response duration, in DLBCL. The L mind trial, although not randomized, suggests, given the higher ORR and CR than revlimid monotherapy studies, that inhibition of cd19 with this antibody may add to the efficacy